Company Contents
Quick Facts & Snapshot
Summary
The Advanced Therapy Medicinal Products (ATMP) CDMO market is entering a rapid scale-up phase, driven by late-stage cell and gene therapy pipelines, regulatory clarity, and pressure to de-risk manufacturing. Leading Advanced Therapy Medicinal Products (ATMP) CDMO market companies are capturing share through global capacity expansion and platform technologies, as revenues grow from US$ 8.40 Billion in 2025 toward US$ 24.98 Billion by 2032 at 17.60% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
Rankings of Advanced Therapy Medicinal Products (ATMP) CDMO market companies are derived from a composite scoring model that blends quantitative and qualitative metrics. Quantitatively, we assess 2025 ATMP CDMO revenue, three-year growth, volume of late-stage and commercial projects, and installed GMP footprint across viral vectors, cell therapies, and RNA platforms. Qualitative dimensions include technology differentiation, digitalization maturity, regulatory track record, breadth of development-to-commercial services, geographic coverage, and ability to structure long-term, multi-asset manufacturing partnerships. Each factor receives a weight reflecting its impact on sponsor decision-making, with revenue and commercial portfolio slightly prioritized. Scores are normalized, peer-benchmarked, and validated against disclosed contracts, facility expansions, and M&A actions. The final ranking reflects sustainable competitive strength rather than short-term deal wins.
Top 10 Companies in Advanced Therapy Medicinal Products (ATMP) CDMO
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Lonza Group AG
Lonza is a global leader among Advanced Therapy Medicinal Products (ATMP) CDMO market companies, offering integrated development-to-commercial manufacturing for cell and gene therapies.
Catalent, Inc. (before divestiture/asset sales)
Catalent is a major global CDMO with strong viral vector, plasmid DNA, and ATMP fill-finish capabilities serving diversified sponsors.
Thermo Fisher Scientific (Patheon Pharmaceuticals)
Thermo Fisher combines CDMO services with equipment, consumables, and reagents, providing an integrated ecosystem for ATMP sponsors.
Samsung Biologics
Samsung Biologics leverages large-scale biologics experience to rapidly build competitive ATMP CDMO capabilities, targeting global sponsors.
WuXi Advanced Therapies (WuXi AppTec group)
WuXi Advanced Therapies is a fully integrated ATMP CDMO platform spanning plasmid, vector, cell therapy and testing services.
FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth is a diversified biologics and ATMP CDMO with strong presence in viral vectors and complex biologics.
Boehringer Ingelheim BioXcellence
Boehringer Ingelheim BioXcellence extends a long-standing biologics CDMO business into ATMP manufacturing for select clients.
Cognate BioServices (Charles River Laboratories)
Cognate BioServices, part of Charles River, specializes in cell therapy CDMO solutions with integrated testing and preclinical support.
Minaris Regenerative Medicine
Minaris Regenerative Medicine focuses on regenerative and cell therapies, supporting clinical-to-commercial manufacturing globally.
Oxford Biomedica Solutions
Oxford Biomedica Solutions is a specialist viral vector CDMO with deep expertise in lentiviral and AAV technologies.
SWOT Leaders
Lonza Group AG
SWOT Snapshot
Deep commercial ATMP experience, broad modality coverage, global GMP network, and strong regulatory track record across major markets.
Premium pricing versus mid-tier Advanced Therapy Medicinal Products (ATMP) CDMO market companies and complex multi-site coordination requirements.
Rising wave of commercial cell and gene launches, long-term capacity reservation deals, and digitalization of CGT manufacturing.
New mega-CDMO entrants, sponsor insourcing for strategic assets, and regulatory changes increasing cost of compliance.
Catalent, Inc. (before divestiture/asset sales)
SWOT Snapshot
Strong viral vector and fill-finish expertise, diversified client base, and established relationships with large pharma sponsors.
Network complexity, historical operational challenges, and exposure to portfolio restructuring and asset divestiture risks.
Refocusing on high-value ATMP platforms, improving reliability, and deepening strategic partnerships with leading gene therapy sponsors.
Rising competition from specialized ATMP CDMOs, capacity overhang risk, and sponsor preference for de-risked manufacturing networks.
Thermo Fisher Scientific (Patheon Pharmaceuticals)
SWOT Snapshot
Integrated ecosystem of CDMO services, equipment, reagents, and analytics, with strong brand and global reach.
Potential conflicts between internal product and CDMO businesses and complex organizational structure for ATMP sponsors to navigate.
Cross-selling into installed instrument base, expanding capacity in key hubs, and enabling standardized platform manufacturing.
Aggressive pricing from stand-alone CDMOs, regulatory scrutiny, and macroeconomic pressures on capital-intensive expansions.
Advanced Therapy Medicinal Products (ATMP) CDMO Market Regional Competitive Landscape
North America remains the largest regional market, driven by a dense pipeline of cell and gene therapy trials and strong venture funding. Lonza Group AG, Catalent, Thermo Fisher Scientific and WuXi Advanced Therapies anchor capacity in the United States, while regulatory expectations from the FDA push Advanced Therapy Medicinal Products (ATMP) CDMO market companies toward robust analytics and comparability packages.
Europe shows accelerating ATMP CDMO demand, anchored by strong academic clusters, supportive HTA frameworks for rare diseases, and EMA-driven regulatory harmonization. FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim BioXcellence, Minaris Regenerative Medicine and Oxford Biomedica Solutions benefit from proximity to European gene therapy developers and long-term partnerships with large pharma headquartered in the region.
Asia Pacific is the fastest-growing region, with Japan, South Korea, China and Singapore promoting regenerative medicine and advanced therapies through regulatory innovation and investment incentives. Samsung Biologics and WuXi Advanced Therapies expand aggressively, while international Advanced Therapy Medicinal Products (ATMP) CDMO market companies evaluate joint ventures and local facilities to secure access to clinical pipelines and manage cost.
China is evolving from a capacity-outsourcing hub to a full innovation ecosystem, supporting domestic gene and cell therapy developers as well as global sponsors. WuXi Advanced Therapies leverages integrated testing and manufacturing, while other Advanced Therapy Medicinal Products (ATMP) CDMO market companies confront geopolitical sensitivities, data localization requirements and dual-sourcing expectations from multinational clients.
Japan and broader East Asia emphasize regenerative medicine and hospital-based cell therapies, creating demand for specialized, small-batch and autologous-focused services. Minaris Regenerative Medicine and regional players collaborate closely with academic medical centers, while global Advanced Therapy Medicinal Products (ATMP) CDMO market companies explore partnerships to navigate local regulations and culturally embedded care models.
Middle East and Latin America remain nascent but increasingly strategic, as governments invest in oncology and rare disease infrastructure. Most Advanced Therapy Medicinal Products (ATMP) CDMO market companies currently serve these regions from U.S. or European sites, yet early discussions around localized fill-finish, technology transfer and training centers indicate the next phase of regionalization.
Advanced Therapy Medicinal Products (ATMP) CDMO Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Emerging specialist in AAV and LVV viral vectors, leveraging Nationwide Children’s Hospital expertise to offer flexible, sponsor-friendly development-to-commercial services.
Focused on rapid clinical-stage viral vector manufacturing, promising shortened lead times via standardized platforms and streamlined tech transfer processes.
Large emerging campus combining plasmid, vector, cell therapy and testing under one roof, targeting seamless scale-up for advanced therapy innovators.
Developing decentralized, point-of-care CAR-T manufacturing solutions that may disrupt centralized ATMP CDMO capacity models over the medium term.
Expanding AAV and LVV capacity with strong European regulatory expertise, positioning as a cost-competitive alternative to larger incumbents.
Specializes in iPSC-based therapies and complex cell programs, emphasizing tailored CMC solutions for next-generation regenerative medicine sponsors.
Advanced Therapy Medicinal Products (ATMP) CDMO Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Advanced Therapy Medicinal Products (ATMP) CDMO market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Advanced Therapy Medicinal Products (ATMP) CDMOmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.